Skip to main content
SpringerLink
Log in

Hirudin, a new therapeutic tool?

  • Review
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

Hirudin is the most potent natural inhibitor of thrombin known to date. It is gaining popularity as an anticoagulant now that recombinant and synthesized forms are available. It is a monospecific and co-factor-independent thrombin inhibitor with otherwise inert pharmacological properties. Being a surprisingly weak immunogen, its administration has exhibited no side effects, particularly on platelets. Bleeding complications are not to be expected at therapeutic doses. Effective anticoagulatory doses can be easily predicted and laboratory control is no problem. Application of hirudin or derivatives thereof may be indicated for: prophylaxis and treatment of postoperative venous thrombosis and diffuse microthrombosis; prevention of arterial thrombosis, especially in cardiac surgery; enhancement of fibrinolytic therapy and/or angioplasty to prevent reocclusion; extracorporeal circulation; and plastic surgery. Hirudin may be a particularly useful alternative anticoagulatory agent in patients sensitized to heparin or in patients with hereditary or acquired antithrombin III deficiency. However, whether hirudin is really an effective therapeutic tool and whether it can replace heparin in certain clinical indications can be judged only after extended clinical experience has been accumulated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Agnelli G, Pascucci C, Cosmi B, Nenci GG (1990) The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 63: 204–207

    Google Scholar 

  2. Bichler J, Fichtl B, Siebeck M, Fritz H (1988) Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Drug Res 38: 704–710

    Google Scholar 

  3. Bichler J, Siebeck M, Spannagl M, Fritz H, Schramm W, Recombinant hirudin: effects of single and repeated subcutaneous administrations of different doses in healthy volunteers. Drug Res., submitted

  4. Bichler J, Gemmerli R, Fritz H (1991) Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons. Thromb Res 61: 39–51

    Google Scholar 

  5. Bichler J, Siebeck M, Maschler R, Pelzer H, Fritz H (1991) Determination of hirudin-thrombin complex in plasma with an enzyme-linked immunosorbent assay. Blood Coagulation Fibrinolysis 2: 129–133

    Google Scholar 

  6. Bizios R, Lai L, Fenton II JW, Sonder SA, Malik AB (1985) Thrombin-induced aggregation of lymphocytes: non-enzymic induction by an hirudin blocked thrombin exosite. Thromb Res 38: 424–429

    Google Scholar 

  7. Bourdon P, Maraganore JM (1989) Effects of BG8865 on thrombin-catalyzed protein-C activation in vitro. Thromb Haemost 62: 534

    Google Scholar 

  8. Braun PJ (1990) Binding properties of hirudin determined by gel filtration and gel electrophoresis. Thromb Res 59: 657–662

    Google Scholar 

  9. Brüggener E, Walsmann P, Markwardt F (1989) Neutralization of hirudin anticoagulant action by DIP-thrombin. Pharmazie 44: 648–649

    Google Scholar 

  10. Bucha E, Markwardt F, Nowak G (1990) Hirudin in haemodialysis. Thromb Res 60: 445–455

    Google Scholar 

  11. Chang JY (1983) The functional domain of hirudin, a thrombin-specific inhibitor. FEBS Lett 164: 307–313

    Google Scholar 

  12. Dennis S, Wallace A, Hofsteenge J, Stone SR (1990) Use of fragments of hirudin to investigate thrombin-hirudin interaction. Eur J Biochem 188: 61–66

    Google Scholar 

  13. Dodt J, Seemüller U, Maschler R, Fritz H (1985) The complete covalent structure of hirudin. Biol Chem Hoppe Seyler 366: 379–385

    Google Scholar 

  14. Dukes GE, Sanders SW, Russo J, Swenson E, Burnakis TG, Saffle JR, Warde GD (1984) Transaminase elevations in patients receiving bovine or porcine heparin. Ann Intern Med 100: 646–650

    Google Scholar 

  15. Freund M, Cazenave JP, Courtney M, Degryse E, Roitsch C, Bernt A, Delebassee D, Defreyn G, Maffrand JP (1990) Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb Haemost 63: 187–192

    Google Scholar 

  16. Friedberg RC, Hagen PO, Pizzo SV (1988) The role of endothelium in factor Xa regulation: the effect of plasma proteinase inhibitors and hirudin. Blood 71: 1321–1328

    Google Scholar 

  17. Gallus AS (1989) Overview of the management of thrombotic disorders. Semin Thromb Hemost 15: 99–110

    Google Scholar 

  18. Gemmerli R (1987) Untersuchungen zur perkutanen Absorption und zur renalen Elimination des Blutegelwirkstoffes Hirudin bei Tier (Schwein, Pavian) und Mensch. Thesis, Munich University

  19. Glusa E, Markwardt F (1990) Platelet functions in recombinant hirudin-anticoagulated blood. Haemostasis 20: 112–118

    Google Scholar 

  20. Grütter MG, Priestle JP, Rahuel J, Grossenbacher H, Bode W, Hofsteenge J, Stone SR (1990) Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J 9: 2361–2365

    Google Scholar 

  21. Hauptmann J, Brüggener E, Markwardt F (1987) Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats. Haemostasis 17: 321–328

    Google Scholar 

  22. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V (1989) Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation 79: 657–665

    Google Scholar 

  23. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V (1990) Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 82: 1476–1484

    Google Scholar 

  24. Hoffmann H, Siebeck M, Spannagl M, Weis M, Geiger R, Jochum M, Fritz H (1990) Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs. Am Rev Respir Dis 142: 782–788

    Google Scholar 

  25. Hofsteenge J, Taguchi H, Stone SR (1986) Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. Biochem J 237: 243–251

    Google Scholar 

  26. Hubbard T, Bacher P, Walenga JM, Fareed J, Galal H (1991) Use of recombinant hirudin to increase the patency rate of microanastomosis in a rabbit model. Blood Coagulation Fibrinolysis 2: 101–103

    Google Scholar 

  27. Ibbotson SH, Grant PJ, Kerry R, Findlay VS, Prentice CRM (1991) The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDVAP) in vivo on the anticoagulant effect of recombinant hirudin (CGP 39393) in vitro. Thromb Haemost 65: 64–66

    Google Scholar 

  28. Ito R, Phaneauf MD, LoGerfo FW (1991) Thrombin inhibition by covalently bound hirudin. Blood Coagulation Fibrinolysis 2: 77–81

    Google Scholar 

  29. Jakubowski JA, Maraganore JM (1990) Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 75: 399–406

    Google Scholar 

  30. Kaiser B, Simon A, Markwardt F (1990) Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb Haemost 63: 44–47

    Google Scholar 

  31. Klöcking HP, Güttner J, Fink E, Markwardt F (1990) Studies in toxicity of recombinant hirudin. Blut 60: 129

    Google Scholar 

  32. Konno S, Fenton II JW, Villanueva GB (1988) Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin. Arch Biochem Biophys 267: 158–166

    Google Scholar 

  33. Krstenansky JL, Broersma RJ, Owen TJ, Payne MH, Yates MT, Mao SJT (1990) Development of MDL 28,050, a small stable antithrombin agent based on a functional domain of the leech protein, hirudin. Thromb Haemost 63: 208–214

    Google Scholar 

  34. Krstenansky JL, Mao SJT (1987) Antithrombin properties of C-terminus of hirudin using synthetic unsulfated Nα-acetylhirudin 45–65. FEBS Lett 211: 10–16

    Google Scholar 

  35. Lindhout T, Blezer R, Hemker C (1990) The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 64: 464–468

    Google Scholar 

  36. Mao SJT, Yates MT, Owen TJ, Krstenansky JL (1988) Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity. Biochemistry 27: 8170–8173

    Google Scholar 

  37. Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL (1989) Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 264: 8692–8698

    Google Scholar 

  38. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW II (1990) Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29: 7095–7101

    Google Scholar 

  39. Markwardt F (1955) Untersuchungen über Hirudin. Naturwissenschaften 42: 537–538

    Google Scholar 

  40. Markwardt F (1956) Die antagonistische Wirkung des Hirudins gegen Thrombin in vivo. Naturwissenschaften 43: 111

    Google Scholar 

  41. Markwardt F (1985) Pharmacology of hirudin. Biomed Biochim Acta 44: 1007–1014

    Google Scholar 

  42. Markwardt F (1989) Development of hirudin as an antithrombotic agent. Sem Thromb Hemostas 15: 269–282

    Google Scholar 

  43. Markwardt F, Hauptmann J, Nowak G, Kleßen C, Walsmann P (1982) Pharmacological studies on the antithrombin action of hirudin in experimental animals. Thromb Haemost 47: 226–229

    Google Scholar 

  44. Markwardt F, Nowak G, Stürzebecher J, Grießbach U, Walsmann P, Vogel G (1984) Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 52: 160–163

    Google Scholar 

  45. Markwardt F, Nowak G, Stürzebecher J, Vogel G (1988) Clinicopharmacological studies with recombinant hirudin. Thromb Res 52: 393–400

    Google Scholar 

  46. Markwardt F, Fink G, Kaiser B, Klöcking HP, Nowak G, Richter M, Stürzebecher J (1988) Pharmacological survey of recombinant hirudin. Pharmazie 43: 202–207

    Google Scholar 

  47. Meyer BH, Luus HG, Müller FO, Badenhorst PN, Röthig HJ (1990) The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J 78: 268–270

    Google Scholar 

  48. Minar E, Zazgornik J (1985) Local hirudin application — an aid in preventing occlusion of an arteriovenous fistula in dialysis patients? Klin Wochenschr 63: 190–191

    Google Scholar 

  49. Mruk JS, Chesebro JH, Webster MWJ, Heras M, Grill DE, Fuster V (1990) Hirudin markedly enhances thrombolysis with r-tPA. Circulation 83: (Abstract no. 0553)

  50. Moncada R, Farred D, Hoppenstadt D, Walenga JM, Fareed J (1990) Comparative studies on the procoagulant actions of intravascular radiocontrast agents and their pharmacological modulation. Blut 60: 123

    Google Scholar 

  51. Naski MC, Fenton II JW, Maraganore JM, Olson ST, Shafer JA (1990) The COOH-terminal domain of hirudin. J Biol Chem 265: 13484–13489

    Google Scholar 

  52. Nowak G, Markwardt F (1980) Influence of hirudin on endotoxin-induced disseminated intravascular coagulation (DIC) in weaned pigs. Exp Pathol 18: 438–443

    Google Scholar 

  53. Prescott SM, Seeger AR, Zimmerman GA, Mc Intyre TM, Maraganore JM (1990) Hirudin-based peptides block the inflammatory effects of thrombin on endothelial cells. J Biol Chem 265: 9614–9616

    Google Scholar 

  54. Richter M, Walsmann P, Markwardt F (1989) Plasma level of dextran-r-hirudin. Pharmazie 44: 73

    Google Scholar 

  55. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton II JW (1990) The structure of a complex of recombinant hirudin and human α-thrombin. Science 249: 277–280

    Google Scholar 

  56. Scharf M, Engels J, Tripier D (1989) Primary structures of new “iso-hirudins”. FEBS Lett 255: 105–110

    Google Scholar 

  57. Shifman MA, Pizzo SV (1982) The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem 257: 3243–3248

    Google Scholar 

  58. Spannagl M, Bichler J, Birg A, Lill H, Schramm W (1991) Chromogenic substrate assay for determination of hirudin in plasma. Blood Coagulation Fibrinolysis 2: 121–127

    Google Scholar 

  59. Spinner S, Stöffler G, Fink E (1986) Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin. J Immunol Methods 87: 79–83

    Google Scholar 

  60. Stone SR, Hofsteenge J (1986) Kinetics of the inhibition of thrombin by hirudin. Biochemistry 25: 4622–4628

    Google Scholar 

  61. Talbot MD, Ambler J, Butler KD, Findlay VS, Mitchell KA, Peters RF, Tweed MF, Wallis RB (1989) Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemost 61: 77–80

    Google Scholar 

  62. Tsiang M, Lentz SR, Dittman WA, Wen D, Scarpati EM, Sadler JE (1990) Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogs. Biochemistry 29: 10602–10612

    Google Scholar 

  63. Verstraete M, Hoet B, Tornai I, Stockmans P, Arnout J (1989) Hirudin, a specific thrombin inhibitor: pharmacokinetics and hemostatic effects in man. Circulation 80: [Suppl 4] (Abstract no. 1673)

  64. Vogel G (1990) Erste klinische Erfahrungen mit Hirudin. In: 6. Kongreß der Gesellschaft für Thrombose- und Hämostase-forschung. Kiel, 21.–24. Februar 1990, Hauptvorträge — ausgewählte freie Vorträge. Schattauer, Stuttgart — New York 1990, p 186

    Google Scholar 

  65. Wallace A, Dennis S, Hofsteenge J, Stone SR (1989) Contribution of the N-terminal region of hirudin to its interaction with thrombin. Biochemistry 28: 10079–10084

    Google Scholar 

  66. Wallis RB (1988) Hirudins and the role of thrombin: lessions from leeches. TIPS 9: 425–427

    Google Scholar 

  67. Walsmann P (1988) Über den Einsatz des spezifischen Thrombininhibitors Hirudin für diagnostische und biochemische Untersuchungen. Pharmazie 43: 737–744

    Google Scholar 

  68. Walsmann P, Maksimenko AV, Abramova V (1989) Hirudin binding to soluble dextran. Pharmazie 44: 72–73

    Google Scholar 

  69. Weitz JI, Hudoba M, Maraganore JM, Hirsh J (1990) Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86: 385–391

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Chemistry and Clinical Biochemistry at the Surgical Clinic City, University of Munich, Nussbaumstrasse 20, W-8000, Munich 2, Germany

    J. Bichler & H. Fritz

Authors
  1. J. Bichler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Fritz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bichler, J., Fritz, H. Hirudin, a new therapeutic tool?. Ann Hematol 63, 67–76 (1991). https://doi.org/10.1007/BF01707275

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01707275

Key words

Search

Navigation